Latest Capital Investments News

Lynas Rare Earths reported FY25 results featuring record NdPr output and the first commercial heavy rare earths production outside China, alongside a $750 million equity raise to fund its ambitious Towards 2030 growth strategy.

Lynas Rare Earths reports FY25 revenue growth amid profit decline, completes major capital projects, and launches a $750 million equity raise to fund its expansive Towards 2030 strategy.

Lynas Rare Earths reported a 20% revenue increase in FY25 driven by higher NdPr sales, yet net profit fell sharply amid ramp-up costs and market challenges. The company completed key growth projects and unveiled its Towards 2030 strategy focused on downstream expansion.

Westgold Resources has transformed into a top five Australian gold producer following its merger with Karora Resources, delivering record gold production and declaring a 3-cent final dividend.

Ramsay Health Care reported a 6.8% revenue increase and a modest rise in underlying profit for FY25, despite a significant impairment in its UK mental health division. The company maintains a strong dividend and outlines a cautiously optimistic outlook for FY26.

Atlas Arteria’s half-year report for June 2025 reveals stable traffic and revenue growth across its French, German, and US toll road assets, underpinned by disciplined financial management and strategic capital investments.

Gryphon Capital Income Trust has successfully completed a $75 million wholesale placement, issuing 37.5 million new units to institutional investors. The capital raise aims to support the Trust’s portfolio expansion, with a Unit Purchase Plan for existing investors set to follow.

Gryphon Capital Income Trust (ASX, GCI) reported a robust fiscal 2025 with a 41.65% jump in revenue and a substantial capital raise to expand its RMBS/ABS portfolio. The Trust’s net assets topped $1 billion, reflecting strong investor confidence and strategic growth.

Optiscan Imaging Limited has launched a $17.75 million fully underwritten entitlement offer to fund clinical trials, regulatory approvals, and product development. Peters Investments underwrites the offer, potentially increasing its stake to nearly 39%.

Cambium Bio has updated its placement, raising A$2.17 million to fund late-stage clinical trials for its lead ophthalmology product, Elate Ocular®. The capital raise reflects strong investor interest and strategic backing.

Stealth Group Holdings has reported a record-breaking 2025 financial year, with sales climbing 27.6% and net profit more than doubling. The company is accelerating its growth strategy, aiming to more than double sales by 2028.

Stealth Group Holdings has reported a landmark FY25 with sales soaring 27.6% to $145.1 million and net profit more than doubling. The company’s strategic investments and operational discipline set the stage for ambitious growth targets through FY28.